US20160287674A1 - Treatment Type 2 Diabetes Mellitus Patients - Google Patents

Treatment Type 2 Diabetes Mellitus Patients Download PDF

Info

Publication number
US20160287674A1
US20160287674A1 US15/068,286 US201615068286A US2016287674A1 US 20160287674 A1 US20160287674 A1 US 20160287674A1 US 201615068286 A US201615068286 A US 201615068286A US 2016287674 A1 US2016287674 A1 US 2016287674A1
Authority
US
United States
Prior art keywords
insulin
plasma glucose
patient
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/068,286
Other languages
English (en)
Inventor
Christine Roy
Elisabeth SOUHAMI
Nacima Demil
Jenny Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROY, CHRISTINE, SOUHAMI, ELISABETH, DEMIL, Nacima, YE, Jenny
Publication of US20160287674A1 publication Critical patent/US20160287674A1/en
Priority to US15/646,760 priority Critical patent/US10434147B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • Subject of the present invention is a pharmaceutical combination for use in glycemic control, for use in the reduction of the HbA1c value, the fasting plasma glucose or/and the 2 hour postprandial plasma glucose, for use in the prevention of weight gain or/and for inducing weight loss, for use in the reduction of the risk of hypoglycemia, in a type 2 diabetes mellitus patient, said combination comprising
  • type 2 diabetes mellitus In contrast to type 1 diabetes, there is not generally a lack of insulin in type 2 diabetes mellitus but in many cases, particularly in progressive cases, the treatment with insulin is regarded as the most suitable therapy, if required in combination with orally administered anti-diabetic drugs.
  • a particular risk exists for overweight patients suffering from type 2 diabetes mellitus e.g. patients with a body mass index (BMI) ⁇ 30 kg/m 2 .
  • BMI body mass index
  • the risks of diabetes overlap with the risks of overweight, leading e.g. to an increase of cardiovascular diseases compared to type 2 diabetes mellitus patients being of a normal weight.
  • the compound desPro 36 Exendin-4(1-39)-Lys 6 -NH 2 (AVE0010, lixisenatide) is a derivative of Exendin-4.
  • AVE0010 is disclosed as SEQ ID NO:93 in WO 01/04156:
  • SEQ ID NO: 1 lixisenatide (44 amino acids) H-G-E-G-T-F-T-S-D-L-S-K-Q-M-E-E-E-A-V-R-L-F-I-E- W-L-K-N-G-G-P-S-S-G-A-P-P-S-K-K-K-K-K-K-NH 2
  • SEQ ID NO: 2 exendin-4 (39 amino acids) H-G-E-G-T-F-T-S-D-L-S-K-Q-M-E-E-E-A-V-R-L-F-I-E- W-L-K-N-G-G-P-S-S-G-A-P-P-S-NH 2
  • Exendins are a group of peptides which can lower blood glucose concentration.
  • the Exendin analogue lixisenatide is characterised by C-terminal truncation of the native Exendin-4 sequence.
  • Lixisenatide comprises six C-terminal lysine residues not present in Exendin-4.
  • Lixisenatide is also termed des-38-proline-exendin-4(He/oderma suspectum)-(1-39)-peptidylpenta-L-lysyl-L-lysinamide (CAS number 320367-13-3).
  • lixisenatide includes pharmaceutically acceptable salts thereof. The person skilled in the art knows suitable pharmaceutically acceptable salts of lixisenatide.
  • Insulin glargine is an analogue of human insulin.
  • Insulin glargine is 31 B -32 B -Di-Arg human insulin with further substitution of asparagine in position A21 by glycine.
  • Insulin glargine is also termed Gly(A21)-Arg(B31)-Arg(B32) human insulin.
  • the CAS number of insulin glargine is 160337-95-1.
  • “insulin glargine” includes pharmaceutically acceptable salts thereof. The person skilled in the art knows suitable pharmaceutically acceptable salts of insulin glargine.
  • Metformin is the international nonproprietary name of 1,1-dimethylbiguanide (CAS number 657-24-9). Metformin is a biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus (type 2 diabetes mellitus) not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. Metformin is usually administered orally. However, control of type 2 diabetes mellitus in obese patients by metformin may be insufficient. Thus, in these patients, additional measures for controlling type 2 diabetes mellitus may be required. “Metformin”, as used herein, included pharmaceutically acceptable salts thereof. The person skilled in the art knows suitable pharmaceutically acceptable salts of metformin.
  • the effect of the combination of lixisenatide, insulin glargine and optionally metformin has been tested in obese type 2 diabetes mellitus patients poorly controlled with a basal insulin alone or a basal insulin in combination with one to three oral anti-diabetic drugs selected from metformin, sulfonylureas, dipeptidyl-peptidase-4 (DPP-4) inhibitors and glinides.
  • the diabetes patients still had a fasting plasma glucose concentration of about 9.2 to 9.5 mmol/L and a HbA1c value of about 8.5%.
  • the 2 hour postprandial plasma glucose was about 13.8 to 14.5 mmol/L (249 to 262 mg/dL). These values still exceed normoglycemic values.
  • insulin glargine combined with lixisenatide and optionally metformin may become a preferred option, attaining meaningful glycemic targets with less hypoglycemia and with weight loss compared with prandial insulin (such as insulin glulisine), as basal insulin plus oral anti-diabetic compounds or basal insulin plus prandial insulin (bolus administration) in difficult to control, obese, insulin-treated type 2 diabetes mellitus patients.
  • prandial insulin such as insulin glulisine
  • a first aspect of the present invention is a pharmaceutical combination for use in glycemic control in a type 2 diabetes mellitus patient, said combination comprising
  • the type 2 diabetes mellitus to be treated preferably is not adequately controlled with compound (b) and optionally compound (c) alone.
  • the combination as described herein can be used for improving glycemic control.
  • “improvement of glycemic control” or “glycemic control” in particular refers to improvement of the 2 hour postprandial plasma glucose concentration, improvement of fasting plasma glucose concentration, or/and improvement of the HbA 1c value.
  • “improvement of glycemic control” or “glycemic control” includes the improvement of the 2 hour postprandial plasma glucose concentration.
  • “improvement of glycemic control” or “glycemic control” includes the reduction of the 2 hour postprandial plasma glucose concentration. Reduction means in particular that the 2 hour postprandial plasma glucose concentration reaches normoglycemic values or at least approaches these values.
  • “improvement of glycemic control” or “glycemic control” includes the improvement of the fasting plasma glucose concentration.
  • improvement of fasting plasma glucose concentration includes the reduction of the fasting plasma glucose concentration.
  • Reduction means in particular that the fasting plasma glucose concentration reaches normoglycemic values or at least approaches these values.
  • “improvement of glycemic control” or “glycemic control” includes the improvement of the HbA 1c value.
  • improvement of the HbA 1c value includes the reduction of the HbA 1c value.
  • Reduction of the HbA 1c value in particular means that the HbA 1c value is reduced below 6.5% or 7%.
  • Yet another aspect of the present invention is a pharmaceutical combination for use in the improvement of the HbA1c value, the fasting plasma glucose or/and the 2 hour postprandial plasma glucose in a type 2 diabetes mellitus patient, said combination comprising
  • the type 2 diabetes mellitus to be treated preferably is not adequately controlled with compound (b) and optionally compound (c) alone.
  • normoglycemic values are blood glucose concentrations of in particular 60-140 mg/d 1 (corresponding to 3.3 to 7.8 mmol/L). This range refers in particular to blood glucose concentrations under fasting conditions and postprandial conditions.
  • Criteria for a type 2 diabetes mellitus diagnosis include:
  • Type 2 Diabetes should not be based on a single plasma glucose concentration. Diagnosis may require continued observation with fasting or/and postprandial blood glucose levels or/and an oral glucose tolerance test.
  • fasting plasma glucose (FPG) and post challenge (postload) glucose can be classified as follows:
  • OGTT Oral Glucose Tolerance Test
  • Impaired glucose tolerance (IGT) and impaired fasting glucose concentration (IFG) are intermediate stages in the natural history of disordered carbohydrate metabolism between normal glucose homeostasis and diabetes.
  • normoglycemic values of fasting plasma glucose are blood glucose concentrations of in particular ⁇ 5.6 mmol/L.
  • normoglycemic values of postprandial plasma glucose are blood glucose concentrations of in particular ⁇ 7.8 mmol/L.
  • not adequately controlled by a particular anti-diabetic treatment means that this treatment is not sufficient to remove the symptoms of type 2 diabetes mellitus.
  • “not adequately controlled” by this treatment means that the patient does not reach normoglycemic values in terms of, for example, 2 hour postprandial plasma glucose concentration, HbA1c value or/and fasting plasma glucose concentration.
  • the type 2 diabetes mellitus patient to be treated according to the present invention may be a subject suffering from type 2 diabetes mellitus, wherein type 2 diabetes mellitus is not adequately controlled by treatment with a basal insulin monotherapy.
  • the type 2 diabetes mellitus patient to be treated according to the present invention may be a subject suffering from type 2 diabetes mellitus, wherein type 2 diabetes mellitus is not adequately controlled by treatment with a combination of a basal insulin and metformin alone, for instance with (a) a dose of at least 1.0 g/day metformin or at least 1.5 g/day metformin for at least 3 months, or/and (b) a dose of at the maximum 2.0 g/day metformin for at least 3 months or at the maximum 3.5 g/day metformin for at least 3 months.
  • the type 2 diabetes mellitus patient to be treated according to the present invention may be a subject suffering from type 2 diabetes mellitus, wherein the type 2 diabetes mellitus to be treated is not adequately controlled with compound (b) and optionally compound (c) alone.
  • Basal insulin includes insulin glargine, insulin detemir and isophane insulin (NPH insulin).
  • the basal insulin is in particular selected from insulin glargine, insulin detemir and isophane insulin (NPH insulin).
  • “to be treated according to the present invention”, “treatment according to the present invention”, or “therapy according to the present invention” relates to the treatment of a type 2 diabetes mellitus patient by the pharmaceutical combination comprising
  • a further aspect of the present invention is a pharmaceutical combination for use in the prevention of weight gain or/and for inducing weight loss, in a type 2 diabetes mellitus patient, said combination comprising
  • the type 2 diabetes mellitus to be treated preferably is not adequately controlled with compound (b) and optionally compound (c) alone.
  • the examples of the present invention demonstrate that the claimed combination can reduce body weight in type 2 diabetes patients, as defined herein, wherein the comparative treatment (insulin glulisine once daily or three times daily) induces a significant weight gain.
  • Yet another aspect of the present invention is a pharmaceutical combination for use in the reduction of the risk of hypoglycemia, in a type 2 diabetes mellitus patient, said combination comprising
  • the type 2 diabetes mellitus to be treated preferably is not adequately controlled with compound (b) and optionally compound (c) alone.
  • the examples of the present invention demonstrate that documented hypoglycemia was numerically and significantly lower with the claimed combination in view of the comparative treatment with insulin glulisine once daily or three times daily.
  • hypoglycemia is the critical limiting factor in the glycemic management of diabetes in both the short and long term. Despite steady improvements in the glycemic management of diabetes, population-based data indicate that hypoglycemia continues to be a major problem for people with both type 1 and type 2 diabetes (American diabetes association, workgroup on hypoglycemia: Defining and Reporting Hypoglycemia in Diabetes. Diabetes Care 28(5), 2005, 1245-1249).
  • the combination of the present invention can prevent hypoglycemia when administered to a type 2 diabetes mellitus patient, as described herein.
  • Prevention of hypoglycemia includes reduction of the number of hypoglycemic events and/or the severity of hypoglycemia events.
  • the combination as described herein is suitable for use in the prevention of hypoglycemia.
  • hypoglycemia is a condition wherein a type 2 diabetes mellitus patient experiences a plasma glucose concentration of below 70 mg/dL (or below 3.9 mmol/L), below 60 mg/dL (or below 3.3 mmol/L), below 54 mg/dL (or below 3.0 mmol/L), below 50 mg/dL, below 40 mg/dL, or below 36 mg/dL.
  • symptomatic hypoglycemia or “symptomatic hypoglycemic event” is a condition associated with a clinical symptom that results from the hypoglycemia, wherein the plasma glucose concentration can be below 70 mg/dL (or below 3.9 mmol/L), below 60 mg/dL (or below 3.3 mmol/L), below 54 mg/dL (or below 3.0 mmol/L), below 50 mg/dL, or below 40 mg/dL.
  • a clinical symptom can be, for example, sweating, palpitations, hunger, restlessness, anxiety, fatigue, irritability, headache, loss of concentration, somnolence, psychiatric disorders, visual disorders, transient sensory defects, transient motor defects, confusion, convulsions, and coma.
  • one or more clinical symptoms of symptomatic hypoglycemia can be selected.
  • Symptomatic hypoglycemia may be associated with prompt recovery after oral carbohydrate administration.
  • a symptomatic hypoglycemia event preferably has a plasma glucose concentration of below 60 mg/dL (or below 3.3 mmol/L).
  • “severe symptomatic hypoglycemia” or “severe symptomatic hypoglycemic event” is a condition with a clinical symptom, as indicated herein, that results from hypoglycemia, wherein the plasma glucose concentration can be below 70 mg/dL (or below 3.9 mmol/L), below 54 mg/dL (or below 3.0 mmol/L) or below 36 mg/dL (or below 2.0 mmol/L).
  • Severe symptomatic hypoglycemia can be associated with acute neurological impairment resulting from the hypoglycemic event.
  • the patient may require the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.
  • a severe symptomatic hypoglycemia event preferably has a plasma glucose concentration of below 36 mg/dL (or below 2.0 mmol/L).
  • severe symptomatic hypoglycemia may include all episodes in which neurological impairment is severe enough to prevent self-treatment and which were thus thought to place patients at risk for injury to themselves or others.
  • the acute neurological impairment may be at least one selected from somnolence, psychiatric disorders, visual disorders, transient sensory defects, transient motor defects, confusion, convulsions, and coma.
  • “Requires assistance” means that the patient could not help himself or herself. Assisting a patient out of kindness, when assistance is not required, should not be considered a “requires assistance” incident.
  • Severe symptomatic hypoglycemia may be associated with prompt recovery after oral carbohydrate, intravenous glucose, or/and glucagon administration.
  • “documented symptomatic hypoglycemia” or “documented symptomatic hypoglycemic event” is an event during which typical symptoms of hypoglycemia accompanied by a measured plasma glucose concentration of 5. 70 mg/dL (5. 3.9 mmol/L), or less than or equal to 54 mg/dL (5 3.0 mmol/L).
  • Clinical symptoms that are considered to result from a hypoglycemic episode are, e.g., increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, coma.
  • asymptomatic hypoglycemia or “asymptomatic hypoglycemic event” is an event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration less than or equal to 70 mg/dL (3.9 mmol/L), or less than or equal to 54 mg/dL (3.0 mmol/L).
  • probable symptomatic hypoglycemia or “probable symptomatic hypoglycemic event” is an event during which symptoms of hypoglycemia are not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose concentration less than or equal to 70 mg/dL (or less than or equal to 3.9 mmol/L), or less than or equal to 54 mg/dL (or less than or equal to 3.0 mmol/L); symptoms treated with oral carbohydrate without a test of plasma glucose.
  • “relative hypoglycemia” or “relative hypoglycemic event” is an event during which the person with diabetes reports any of the typical symptoms of hypoglycemia, and interprets the symptoms as indicative of hypoglycemia, but with a measured plasma glucose concentration greater than 70 mg/dL (or greater than 3.9 mmol/L).
  • the hypoglycemia can be a symptomatic hypoglycemia, a severe symptomatic hypoglycemia, a documented symptomatic hypoglycemia, a probable symptomatic hypoglycemia, a relative symptomatic hypoglycemia, or an asymptomatic hypoglycemia.
  • a symptomatic hypoglycemia more preferably a severe symptomatic hypoglycemia. “Reducing the risk of hypoglycemia”, as used herein, can include reducing the incidence of hypoglycemia.
  • the incidence of hypoglycemia per patient year can be computed per patient as: 365.25 ⁇ (number of episodes of hypoglycemia)/(number of days exposed) and summarized by type of event and treatment group. “Reducing the risk of hypoglycemia”, as used herein, can further include prevention of hypoglycemia in a patient, when the formulation described herein is administered to a type 2 diabetes mellitus patient, as described herein. “Reducing the risk of hypoglycemia”, as used herein, can further include reduction of the number of hypoglycemic events, and/or the severity of hypoglycemia events.
  • the type 2 diabetes mellitus patient suffering from type 2 diabetes mellitus to be treated according to the present invention may be obese.
  • a patient can be considered as obese if the body mass index is at least 30 kg/m 2 .
  • an obese type 2 diabetes mellitus patient may have a body mass index of at least 30 kg/m 2 .
  • the obese type 2 diabetes mellitus patient may have a body weight of at least 87 kg, at least 88 kg, at least 89 kg or at least 90 kg.
  • the type 2 diabetes mellitus patient may be obese prior to the onset of therapy with the combination according to the present invention.
  • the patient to be treated may have an age of less than 50 years.
  • the patient may also have an age of at least 50 years, or an age in the range of 50 to 64 years.
  • the patient may also have an age of at least 65 years, or an age in the range of 65 to 74 years.
  • the patient may also have an age of at least 75 years. It is preferred that the patient has an age of at least 65 years.
  • the type 2 diabetes mellitus to be treated according to the present invention may suffer from a type 2 diabetes mellitus not adequately controlled with a basal insulin monotherapy or a basal insulin and one to three oral anti-diabetics alone selected from the group consisting of metformin, a sulfonylurea, a DPP-4 inhibitor or a glinide alone.
  • the basal insulin is in particular selected from insulin glargine, insulin detemir and isophane insulin (NPH insulin).
  • this type 2 diabetes mellitus to be treated preferably is not adequately controlled with compound (b) and optionally compound (c) alone.
  • the type 2 diabetes mellitus patient to be treated according to the present invention may have a fasting plasma glucose of at least 9 mmol/L or at least 9.5 mmol/L when treated with a basal insulin monotherapy or a basal insulin and one to three oral anti-diabetics alone selected from the group consisting of metformin, a sulfonylurea, a DPP-4 inhibitor or a glinide alone.
  • the patient may have this fasting plasma glucose of at least 9 mmol/L L or at least 9.5 mmol/L prior to the onset of therapy with the combination according to the present invention.
  • the basal insulin is in particular selected from insulin glargine, insulin detemir and isophane insulin (NPH insulin).
  • this type 2 diabetes mellitus to be treated preferably is not adequately controlled with compound (b) and optionally compound (c) alone.
  • the patient may have a fasting plasma glucose in the range of 5.6 to 6.9 mmol/L when treated with compound (b) and optionally compound (c) alone. This range can be considered to be an impaired fasting plasma glucose concentration.
  • the patient may have a fasting plasma glucose of at least 6.6 mmol/L, at least 6.7 mmol/L, at least 6.8 mmol/L or at least 6.9 mmol/L, when treated with compound (b) and optionally compound (c) alone.
  • the type 2 diabetes mellitus patient to be treated according to the present invention may have a HbA1c of at least 8.5% when treated with a basal insulin monotherapy or a basal insulin and one to three oral anti-diabetics alone selected from the group consisting of metformin, a sulfonylurea, a DPP-4 inhibitor or a glinide alone.
  • the patient may have this a HbA1c of at least 8.5% prior to the onset of therapy with the combination according to the present invention.
  • the basal insulin is in particular selected from insulin glargine, insulin detemir and isophane insulin (NPH insulin).
  • this type 2 diabetes mellitus to be treated preferably is not adequately controlled with compound (b) and optionally compound (c) alone.
  • the patient may have a HbA1c of at least 7.5% or at least 7.8% when treated with compound (b) and optionally compound (c) alone.
  • the patient to be treated according to the present invention does not receive concomitant treatment with at least one of a sulfonylurea, a DPP-4 inhibitor and a glinide.
  • the type 2 diabetes mellitus has been diagnosed for at least 1 year or at least 2 years prior to the onset of a therapy according to the present invention.
  • the administration of the combination according to the present invention can comprise the steps:
  • step (i) or/and (ii) wherein the amount of compound (b) to be administered in steps (i) or/and (ii) is adjusted (titrated) so that a predetermined fasting plasma glucose level or/and a predetermined self-monitored plasma glucose level is reached or at least approximated.
  • adjustment (titration) of compound (b) is performed in steps (i).
  • step (i) the compounds (b) and (c) of the pharmaceutical combination of the present invention may be administered for at least 4 weeks, at least 8 weeks, at least 12 weeks, or at least 16 weeks.
  • step (i) comprises administration of compounds (b) and (c) for at least about 12 weeks.
  • Step (i) may be performed for at the maximum about 8 weeks, at the maximum about 12 weeks, at the maximum about 16 weeks, at the maximum about 20 weeks, or at the maximum about 24 weeks. Preferred is a duration of step (i) of about 12 weeks.
  • Step (i) may be performed with the proviso that compound (a) is not administered.
  • a treatment with a combination of insulin glargine, lixisenatide and optionally metformin can improve fasting plasma glucose concentration, HbA 1c value, body weight and the risk of hypoglycemia if the treatment starts with administration of insulin glargine and optionally metformin alone.
  • the dose of insulin glargine can be reduced.
  • the amount of compound (b) to be administered in steps (i) or/and (ii) is adjusted so that a predetermined fasting plasma glucose level or/and a predetermined self-monitored plasma glucose level is reached or at least approximated.
  • the amount of compound (b) to be administered in steps (i) or/and (ii) may be adjusted on the basis of daily measurements of plasma glucose concentration.
  • the amount of compound (b) to be administered in steps (i) or/and (ii) may adjusted so that
  • SMPG Self-monitored plasma glucose
  • 4-point Self Monitored Plasma Glucose or the “7-point Self Monitored Plasma Glucose”.
  • the 4 point and 7-point Self Monitored Plasma Glucose value are in particular average plasma glucose concentrations including fasting and postprandial conditions.
  • “4-point Self Monitored Plasma Glucose” in particular refers to the measurement of plasma glucose four times a day and calculation of the average plasma glucose concentration therefrom.
  • the 4-point Self Monitored Plasma Glucose measurements are performed pre-breakfast, post-breakfast, pre-dinner, and post-dinner.
  • 7-point Self Monitored Plasma Glucose in particular refers to the measurement of plasma glucose seven times a day and calculation of the average plasma glucose concentration therefrom.
  • the 7-point Self Monitored Plasma Glucose measurements are performed pre-breakfast, post-breakfast, pre-lunch, post-lunch, pre-dinner, post-dinner and at bed-time.
  • the “fasting self-monitored plasma glucose (SMPG)”, as used herein, is measured by the patient before breakfast, in particular before insulin glargine or/and lixisenatide injection and optional intake of metformin.
  • a type 2 diabetes mellitus patient may have a HbA1c value in the range of 7% to 10%.
  • the type 2 diabetes mellitus patient to be treated may have a HbA 1c value of at least about 7%, at least about 7.5%, at least about 7.8%, at least about 8%, at least about 8.5%, or at least about 9%.
  • the type 2 diabetes mellitus patient to be treated according to the present invention may have a 2 hours postprandial plasma glucose concentration of at least 11.1 mmol/L, at least 12 mmol/L, at least 13 mmol/L, at least 13.5 mmol/L or at least 14 mmol/L. These plasma glucose concentrations exceed normoglycemic concentrations, indicating that the type 2 diabetes mellitus is not adequately controlled if treated with an antidiabetic compound, as described herein.
  • Postprandial is a term that is well known to a person skilled in the art of diabetology.
  • the term “postprandial” describes in particular the phase after an ingestion of a meal or/and exposure to glucose under experimental conditions. In a healthy person this phase is characterised by an increase and subsequent decrease in blood glucose concentration.
  • the postprandial phase typically ends up to 2 h after a meal or/and exposure to glucose (2 h postprandial plasma glucose concentration).
  • the type 2 diabetes mellitus patient to be treated according to the invention may have a fasting plasma glucose concentration of at least 8 mmol/L, at least 8.5 mmol/L, at least 9 mmol/L, or at least 9.5 mmol/L. These plasma glucose concentrations exceed normoglycemic concentrations, indicating that the type 2 diabetes mellitus is not adequately controlled if treated with an antidiabetic compound, as described herein.
  • metformin can be administered according to commonly known administration protocols of metformin in accordance with the terms of marketing authorization.
  • metformin can be administrated once daily, twice daily or three times a day.
  • the metformin dose applied before the onset of the therapy as disclosed herein is continued in combination with (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, as disclosed herein.
  • metformin may be administered orally.
  • Metformin may be administered to a type 2 diabetes mellitus patient in need thereof, in an amount sufficient to induce a therapeutic effect.
  • Metformin may be administered in a dose of at least 1.0 g/day or at least 1.5 g/day.
  • Metformin may be administered in a dose of at the maximum of 2.0 g/day or at the maximum of 3.5 g/day.
  • the daily metformin dose can be divided into two or three separate doses.
  • metformin may be formulated in a solid dosage form, such as a tablet or pill.
  • Metformin may be formulated with suitable pharmaceutically acceptable carriers, adjuvants, or/and auxiliary substances.
  • lixisenatide or/and a pharmaceutically acceptable salt may be administered in an add-on therapy to administration of insulin glargine and optionally metformin.
  • the terms “add-on”, “add-on treatment” and “add-on therapy” relate to treatment according to the present invention with insulin glargine and lixisenatide, and optionally metformin.
  • Metformin, insulin glargine or/and lixisenatide each may be administered in a once-a-day-dosage.
  • Metformin, insulin glargine and lixisenatide may be administered by different administration routes.
  • Metformin may be administered orally, and lixisenatide and insulin glargine may be administered parenterally.
  • additives mean that the dose of metformin administered before the onset of the treatment according to the present invention, as disclosed herein, can be continued in the treatment of the present invention.
  • lixisenatide includes pharmaceutically acceptable salts thereof.
  • suitable pharmaceutically acceptable salts of lixisenatide is the acetate salt of lixisenatide.
  • lixisenatide or/and the pharmaceutically acceptable salt thereof may be administered to a type 2 diabetes mellitus patient in need thereof, in an amount sufficient to induce a therapeutic effect.
  • lixisenatide or/and the pharmaceutically acceptable salt thereof may be formulated with suitable pharmaceutically acceptable carriers, adjuvants, or/and auxiliary substances.
  • Lixisenatide or/and a pharmaceutically acceptable salt thereof may be administered parenterally, e.g. by injection (such as by intramuscular or by subcutaneous injection). Suitable injection devices, for instance the so-called “pens” comprising a cartridge comprising the active ingredient, and an injection needle, are known. Lixisenatide or/and a pharmaceutically acceptable salt thereof may be administered in a suitable amount, for instance in an amount in the range of 10 ⁇ g to 20 ⁇ g per dose.
  • lixisenatide or/and a pharmaceutically acceptable salt thereof may be administered in a daily dose in the range of 10 ⁇ g to 20 ⁇ g.
  • Lixisenatide or/and a pharmaceutically acceptable salt thereof may be administered by one injection per day.
  • Lixisenatide or/and a pharmaceutically acceptable salt thereof may be administered about 30 min before breakfast.
  • lixisenatide or/and a pharmaceutically acceptable salt thereof may be provided in a liquid composition, which preferably is an aqueous formulation. It is preferred that the liquid composition is suitable for parenteral administration, in particular for injection.
  • a liquid composition of the present invention may have an acidic or a physiologic pH.
  • An acidic pH preferably is in the range of pH 1-6.8, pH 3.5-6.8, or pH 3.5-5.
  • a physiologic pH preferably is in the range of pH 2.5-8.5, pH 4.0-8.5, or pH 6.0-8.5.
  • the pH may be adjusted by a pharmaceutically acceptable diluted acid (typically HCl) or pharmaceutically acceptable diluted base (typically NaOH).
  • the liquid composition comprising lixisenatide or/and a pharmaceutically acceptable salt thereof may comprise a suitable preservative.
  • a suitable preservative may be selected from phenol, m-cresol, benzyl alcohol and p-hydroxybenzoic acid ester.
  • a preferred preservative is m-cresol.
  • the liquid composition comprising lixisenatide or/and a pharmaceutically acceptable salt thereof may comprise a tonicity agent.
  • a suitable tonicity agent may be selected from glycerol, lactose, sorbitol, mannitol, glucose, NaCl, calcium or magnesium containing compounds such as CaCl 2 .
  • the concentration of glycerol, lactose, sorbitol, mannitol and glucose may be in the range of 100-250 mM.
  • the concentration of NaCl may be up to 150 mM.
  • a preferred tonicity agent is glycerol.
  • the liquid composition comprising lixisenatide or/and a pharmaceutically acceptable salt thereof may comprise methionine from 0.5 ⁇ g/mL to 20 ⁇ g/mL, preferably from 1 ⁇ g/ml to 5 ⁇ g/ml.
  • the liquid composition comprises L-methionine.
  • insulin glargine or/and a pharmaceutically acceptable salt thereof may be provided in a liquid composition, which preferably is an aqueous formulation. It is preferred that the liquid composition is suitable for parenteral administration, in particular for injection. The skilled person knows such liquid compositions of insulin glargine.
  • Surfactants can be added to pharmaceutical formulation comprising insulin glargine, for example, inter alia, non-ionic surfactants.
  • pharmaceutically customary surfactants are preferred, such as, for example: partial and fatty acid esters and ethers of polyhydric alcohols such as of glycerol, sorbitol and the like (Span®, Tween®, in particular Tween® 20 and Tween® 80, Myrj®, Brij®), Cremophor® or poloxamers.
  • the surfactants are present in the pharmaceutical composition in a concentration of 5-200 ⁇ g/ml, preferably of 5-120 ⁇ g/ml and particularly preferably of 20-75 ⁇ g/ml.
  • the formulation comprising insulin glargine or/and a pharmaceutically acceptable salt thereof can additionally contain preservatives (e.g. phenol, m-cresol, p-cresol, parabens), isotonic agents (e.g. mannitol, sorbitol, lactose, dextrose, trehalose, sodium chloride, glycerol), buffer substances, salts, acids and alkalis and also further excipients. These substances can in each case be present individually or alternatively as mixtures.
  • preservatives e.g. phenol, m-cresol, p-cresol, parabens
  • isotonic agents e.g. mannitol, sorbitol, lactose, dextrose, trehalose, sodium chloride, glycerol
  • buffer substances e.g. mannitol, sorbitol, lactose, dextrose, trehalose, sodium chloride, g
  • Glycerol, dextrose, lactose, sorbitol and mannitol can be present in the pharmaceutical formulation comprising insulin glargine or/and a pharmaceutically acceptable salt thereof in a concentration of 100-250 mM, NaCI in a concentration of up to 150 mM.
  • Buffer substances such as, for example, phosphate, acetate, citrate, arginine, glycylglycine or TRIS (i.e. 2-amino-2-hydroxymethyl-1,3-propanediol) buffer and corresponding salts, can be present in a concentration of 5-250 mM, preferably 10-100 mM.
  • Further excipients can be, inter alia, salts or arginine.
  • the zinc concentration of the formulation comprising insulin glargine or/and a pharmaceutically acceptable salt thereof is in the range of the concentration which is reached by the presence of 0-1000 ⁇ g/mL, preferably 20-400 ⁇ g/mL zinc, most preferably 90 ⁇ g/mL.
  • the zinc may be present in form of zinc chloride, but the salt is not limited to be zinc chloride.
  • glycerol and/or mannitol can be present in a concentration of 100-250 mmol/L, and/or NaCl is preferably present in a concentration of up to 150 mmol/L.
  • a buffer substance can be present in a concentration of 5-250 mmol/L.
  • Insulin glargine or/and a pharmaceutically acceptable salt thereof can be present in the pharmaceutical formulation in a concentration of 60-6000 nmol/ml, preferably 240-3000 nmol/ml.
  • the pH of the formulation comprising insulin glargine or/and a pharmaceutically acceptable salt thereof can be in the range of pH 1-6.8, preferably pH 3.5-6.8, more preferred pH 3.5-4.5, even more preferred pH 4.0-4.5.
  • Yet another aspect of the present invention is the use of a combination comprising
  • the patient may be a patient as defined herein.
  • Yet another aspect of the present invention is the use of a combination comprising
  • the fasting plasma glucose or/and the 2 hour postprandial plasma glucose in a type 2 diabetes mellitus patient preferably is not adequately controlled with compound (b) and optionally compound (c) alone.
  • the patient may be a patient as defined herein.
  • Yet another aspect of the present invention is the use of a combination comprising
  • the patient may be a patient as defined herein.
  • Yet another aspect of the present invention is the use of a combination comprising
  • the patient may be a patient as defined herein.
  • Yet another aspect of the present invention is method for glycemic control in a type 2 diabetes mellitus patient, said method comprising administration of a combination comprising
  • the type 2 diabetes mellitus to be treated preferably is not adequately controlled with compound (b) and optionally compound (c) alone.
  • the patient may be a patient as defined herein.
  • Yet another aspect of the present invention is method for the improvement of the HbA1c value, the fasting plasma glucose or/and the 2 hour postprandial plasma glucose in a type 2 diabetes mellitus patient, said method comprising administration the use of a combination comprising
  • the type 2 diabetes mellitus to be treated preferably is not adequately controlled with compound (b) and optionally compound (c) alone.
  • the patient may be a patient as defined herein.
  • Yet another aspect of the present invention is method for the prevention of weight gain or/and for inducing weight loss in a type 2 diabetes mellitus patient, said method comprising administration the use of a combination comprising
  • the type 2 diabetes mellitus to be treated preferably is not adequately controlled with compound (b) and optionally compound (c) alone.
  • the patient may be a patient as defined herein.
  • Yet another aspect of the present invention is method for the reduction of the risk of hypoglycemia in a type 2 diabetes mellitus patient, said method comprising administration the use of a combination comprising
  • the type 2 diabetes mellitus to be treated preferably is not adequately controlled with compound (b) and optionally compound (c) alone.
  • the patient may be a patient as defined herein.
  • FIG. 1 Plot of mean change in HbA1 c(%) from baseline by visit—mITT population
  • FIG. 2 Peak of mean change in body weight (kg) from baseline by visit—mITT population
  • FIG. 3 Plot of mean insulin glargine daily dose (U) by visit—mITT population
  • FIG. 4 Plot of mean daily insulin glulisine dose (U) by visit—mITT population
  • FIG. 5 Plot of mean total insulin dose (U) by visit—mITT population
  • FIG. 6 Graphical study design. 1 Insulin glargine should be injected subcutaneously once daily at dinner or breakfast time (according to patient's/investigators' preference). Injection time (dinner or breakfast) should be fixed at V2 and remain the same throughout the study. 2 Injection of lixisenatide should be performed 30-60 minutes prior to dinner or breakfast (the one associated with the highest self-monitored 2h-PPG median value across 3 different days). Meal used for lixisenatide dosing should remain the same throughout the 26-week treatment period. 3 Injection of insulin glulisine should be done 0 to 15 minutes before dinner or breakfast (the one associated with the highest self-monitored 2h-PPG median value across 3 different days). Meal used for insulin glulisine dosing should remain the same throughout the 26-week treatment period. 4 Injection of insulin glulisine prior to breakfast, lunch and dinner.
  • ECG Electrocardiogram
  • FPG Fasting plasma glucose
  • GLP-1 Glucagon-like peptide-1
  • TID Ter in die (Three times a day)
  • LOCF Last observation carried forward.
  • a Analysis of covariance (ANCOVA) model with treatment groups lixisenatide, insulin glulisine QD, and insulin glulisine TID
  • Visit 7 Wide ⁇ 1 strata of HbA1c [ ⁇ 8.0, ⁇ 8.0%], randomization strata of metformin use, and country as fixed effects and baseline HbA1c value as a covariate.
  • the analysis included measurements obtained up to 14 days after the last injection of the investigational medicinal product. Patients with both baseline and Week 26 (LOCF) measurements are included.
  • insulin glulisine QD or lixisenatide vs. insulin glulisine TID.
  • the analysis included measurements obtained up to 3 days after the last injection of the investigational medicinal product. Patients with both baseline and Week 26 (LOCF) measurements are included.
  • FIG. 1 shows the mean change in HbA1c(%) from baseline by visit in the mITT population.
  • FIG. 2 shows the mean change in body weight (kg) from baseline by visit in the mITT population.
  • LOCF Last observation carried forward.
  • a Analysis of covariance (ANCOVA) model with treatment groups lixisenatide, insulin glulisine QD, insulin glulisine TID
  • the analysis included measurements obtained up to one day after the last injection of the investigational medicinal product. Patients with both baseline and Week 26 (LOCF) measurements are included.
  • LOCF Last observation carried forward.
  • a Analysis of covariance (ANCOVA) model with treatment groups lixisenatide, insulin glulisine QD, insulin glulisine TID
  • the analysis included measurements obtained up to the date of the last injection of the investigational medicinal product. Patients with both baseline and Week 26 (LOCF) measurements are included.
  • FIG. 3 shows the mean insulin glargine daily dose (U) by visit in the mITT population.
  • FIG. 4 shows the mean daily insulin glulisine dose (U) by visit in the mITT population.
  • FIG. 5 shows the mean total insulin dose (U) by visit in the mITT population
  • On-treatment period the time from the first injection of the investigational medicinal product up to 3 days after the last injection of the investigational medicinal product. 1 Calculated as (number of patients with events * 100 divided by total exposure + 3 days in patient years). 2 Calculated as (number of events * 100 divided by total exposure + 3 days in patient years).
  • Co-primary endpoints at 26 weeks were (1) non-inferiority (95% CI upper bound ⁇ 0.4%) in HbA 1c reduction with LIXI vs GLU-1 and (2) for LIXI vs GLU-3, either non-inferiority in HbA 1c reduction (2a) OR superiority (one-sided ⁇ 0.025) in body weight change (2b).
  • FPG, PPG, IG dose, composite outcomes, AEs, and hypoglycemia were assessed.
  • Each arm randomized 298 pts (T2DM duration 12 yrs, BI duration 3 yrs, weight ⁇ 90 kg).
  • AEs adverse events
  • BL baseline
  • CI confidence interval
  • FPG fasting plasma glucose
  • HbA 1c glycated hemoglobin
  • LOCF last observation carried forward
  • LS least squares
  • mITT modified intent-to-treat
  • PPG postprandial glucose
  • QD once daily
  • SD standard deviation
  • SE standard error
  • TID thrice daily.
  • n numbers are for the mITT population (all pts who received ⁇ 1 dose of study medication, with both a baseline assessment and ⁇ 1 post-baseline assessment).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US15/068,286 2015-03-13 2016-03-11 Treatment Type 2 Diabetes Mellitus Patients Abandoned US20160287674A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/646,760 US10434147B2 (en) 2015-03-13 2017-07-11 Treatment type 2 diabetes mellitus patients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15159064 2015-03-13
EP15159064.3 2015-03-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/646,760 Division US10434147B2 (en) 2015-03-13 2017-07-11 Treatment type 2 diabetes mellitus patients

Publications (1)

Publication Number Publication Date
US20160287674A1 true US20160287674A1 (en) 2016-10-06

Family

ID=52684082

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/068,286 Abandoned US20160287674A1 (en) 2015-03-13 2016-03-11 Treatment Type 2 Diabetes Mellitus Patients
US15/646,760 Active US10434147B2 (en) 2015-03-13 2017-07-11 Treatment type 2 diabetes mellitus patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/646,760 Active US10434147B2 (en) 2015-03-13 2017-07-11 Treatment type 2 diabetes mellitus patients

Country Status (22)

Country Link
US (2) US20160287674A1 (https=)
EP (1) EP3268029B1 (https=)
JP (1) JP6857129B2 (https=)
KR (1) KR102694473B1 (https=)
CN (1) CN107921099A (https=)
AR (1) AR103914A1 (https=)
AU (1) AU2016232448C1 (https=)
CA (1) CA2979448A1 (https=)
CL (1) CL2017002293A1 (https=)
EA (1) EA034940B1 (https=)
ES (1) ES2922551T3 (https=)
IL (1) IL254496B (https=)
MA (1) MA42287B1 (https=)
MX (1) MX389091B (https=)
NZ (1) NZ736299A (https=)
PH (1) PH12017501662A1 (https=)
PL (1) PL3268029T3 (https=)
PT (1) PT3268029T (https=)
SG (1) SG11201707372YA (https=)
TN (1) TN2017000373A1 (https=)
TW (1) TWI748945B (https=)
WO (1) WO2016146514A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117909B2 (en) 2008-10-17 2018-11-06 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients
US12186374B2 (en) 2014-12-12 2025-01-07 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US12303598B2 (en) 2009-11-13 2025-05-20 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1-agonist and methionine

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102037996B1 (ko) 2018-03-22 2019-10-29 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포 또는 이의 조정 배지를 포함하는 제2형 당뇨병 예방 또는 치료용 조성물
KR20200132550A (ko) 2019-05-17 2020-11-25 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포 또는 이의 조정 배지를 포함하는 혈관질환 예방 또는 치료용 조성물
KR20190122196A (ko) 2019-10-22 2019-10-29 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포 또는 이의 조정 배지를 포함하는 제2형 당뇨병 예방 또는 치료용 조성물

Family Cites Families (408)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB835638A (en) 1956-12-01 1960-05-25 Novo Terapeutisk Labor As Insulin crystal suspensions having a protracted effect
GB840870A (en) 1957-08-03 1960-07-13 Novo Terapeutisk Labor As Improvements in or relating to insulin preparations
US3758683A (en) 1971-04-30 1973-09-11 R Jackson Insulin product
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1554157A (en) 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
US4153689A (en) 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1527605A (en) 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
US4165370A (en) 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
JPS6033474B2 (ja) 1978-05-11 1985-08-02 藤沢薬品工業株式会社 新規なヒアルロニダ−ゼｂｍｐ−８２３１およびその製造法
DE3064888D1 (en) 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
JPS55153712A (en) 1979-05-18 1980-11-29 Kao Corp Insulin pharmaceutical preparation and its production
DE3033127A1 (de) 1980-09-03 1982-04-08 Hoechst Ag, 6000 Frankfurt Neue analoga des insulins
US4367737A (en) 1981-04-06 1983-01-11 George Kozam Multiple barrel syringe
EP0083619A1 (en) 1981-07-17 1983-07-20 Nordisk Insulinlaboratorium A stable aqueous, therapeutic insulin preparation and a process for preparing it
NL193099C (nl) 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3326472A1 (de) 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
DE3333640A1 (de) 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
US4839341A (en) 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
CA1244347A (en) 1984-05-29 1988-11-08 Eddie H. Massey Stabilized insulin formulations
ATE50502T1 (de) 1984-06-09 1990-03-15 Hoechst Ag Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung.
DE3440988A1 (de) 1984-11-09 1986-07-10 Hoechst Ag, 6230 Frankfurt Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung
US5008241A (en) 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
DK113585D0 (da) 1985-03-12 1985-03-12 Novo Industri As Nye peptider
IL78425A (en) 1985-04-15 1991-05-12 Lilly Co Eli Intranasal formulation containing insulin
US4689042A (en) 1985-05-20 1987-08-25 Survival Technology, Inc. Automatic medicament ingredient mixing and injecting apparatus
DE3526995A1 (de) 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4960702A (en) 1985-09-06 1990-10-02 Codon Methods for recovery of tissue plasminogen activator
DE3636903A1 (de) 1985-12-21 1987-07-02 Hoechst Ag Fusionsproteine mit eukaryotischem ballastanteil
US5496924A (en) 1985-11-27 1996-03-05 Hoechst Aktiengesellschaft Fusion protein comprising an interleukin-2 fragment ballast portion
DE3541856A1 (de) 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
DE3544295A1 (de) 1985-12-14 1987-06-19 Bayer Ag Thermoplastische formmassen mit hoher kriechstromfestigkeit
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
IE62879B1 (en) 1987-02-25 1995-03-08 Novo Nordisk As Novel insulin derivatives
US5034415A (en) 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
DE3726655A1 (de) 1987-08-11 1989-02-23 Hoechst Ag Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
US6875589B1 (en) 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
DE3827533A1 (de) 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
US4923162A (en) 1988-09-19 1990-05-08 Fleming Matthew C Radiation shield swivel mount
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5225323A (en) 1988-11-21 1993-07-06 Baylor College Of Medicine Human high-affinity neurotransmitter uptake system
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
DK0471036T4 (da) 1989-05-04 2004-07-19 Southern Res Inst Indkapslingsfremgangsmåde
GR1005153B (el) 1989-08-29 2006-03-13 The General Hospital Corporation Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.
US5358857A (en) 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins
US5227293A (en) 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
ATE164080T1 (de) 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
US5397771A (en) 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
CA2038597A1 (en) 1991-03-19 1992-09-20 Jose P. Garzaran A method and a pharmaceutical preparation for treating pain
US5614219A (en) 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
US6468959B1 (en) 1991-12-05 2002-10-22 Alfatec-Pharm Gmbh Peroral dosage form for peptide containing medicaments, in particular insulin
CH682806A5 (de) 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
CH682805A5 (de) 1992-02-24 1993-11-30 Medimpex Ets Anzeigeeinrichtung für ein Injektionsgerät.
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5846747A (en) 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5253785A (en) 1992-04-02 1993-10-19 Habley Medical Technology Corp. Variable proportion dispenser
ATE148710T1 (de) 1992-12-02 1997-02-15 Hoechst Ag Verfahren zur gewinnung von proinsulin mit korrekt verbundenen cystinbrücken
FI953001A7 (fi) 1992-12-18 1995-06-16 Lilly Co Eli Insuliinianalogeja
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5478323A (en) 1993-04-02 1995-12-26 Eli Lilly And Company Manifold for injection apparatus
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
JP2837956B2 (ja) 1993-06-21 1998-12-16 ノボ ノルディスク アクティーゼルスカブ Ａｓｐ▲上Ｂ２８▼インスリン結晶
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5534488A (en) 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
EP2283821A1 (en) 1993-11-19 2011-02-16 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
IT1265271B1 (it) 1993-12-14 1996-10-31 Alcatel Italia Sistema di predistorsione in banda base per la linearizzazione adattativa di amplificatori di potenza
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE4405179A1 (de) 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
DE4405388A1 (de) 1994-02-19 1995-08-24 Hoechst Ag Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
ATE416755T1 (de) 1994-03-07 2008-12-15 Nektar Therapeutics Verfahren und zusammensetzung für die pulmonale darreichung von insulin
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5559094A (en) 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
PT779806E (pt) 1994-09-09 2001-02-28 Takeda Chemical Industries Ltd Preparacao de libertacao sustentada contendo um sal metalico de um peptido
US5879584A (en) 1994-09-10 1999-03-09 The Procter & Gamble Company Process for manufacturing aqueous compositions comprising peracids
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
YU18596A (sh) 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US6143718A (en) 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
EP0831922A2 (en) 1995-06-08 1998-04-01 Therexsys Limited Improved pharmaceutical compositions for gene therapy
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
JPH11292787A (ja) 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
DE19637230A1 (de) 1996-09-13 1998-03-19 Boehringer Mannheim Gmbh Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
WO1997046584A1 (de) 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
EP0910402B1 (en) 1996-06-20 2007-08-08 Novo Nordisk A/S Insulin preparations containing mannitol
BR9709845B1 (pt) 1996-06-20 2008-11-18 preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
AU752411B2 (en) 1996-08-13 2002-09-19 Genentech Inc. Formulation
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE122007000044I2 (de) 1997-01-07 2011-05-05 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
WO1998035033A1 (en) 1997-02-05 1998-08-13 1149336 Ontario Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
US6043214A (en) 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
EP1005490B1 (en) 1997-03-20 2006-03-29 Novo Nordisk A/S Zinc free insulin crystals for use in pulmonary compositions
CA2635352C (en) 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
JP2001521006A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
ES2230727T3 (es) 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
ATE383867T1 (de) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
EP1049486A4 (en) 1997-12-05 2006-01-04 Lilly Co Eli GLP-1 FORMULATIONS
WO1999034821A1 (en) 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
EP1054594B1 (en) 1998-02-13 2007-07-04 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
WO1999042482A1 (en) 1998-02-23 1999-08-26 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
ATE413889T1 (de) 1998-06-05 2008-11-15 Nutrinia Ltd Insulin angereichertes säuglingsnährpräparat
EP1119625B1 (en) 1998-10-07 2005-06-29 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
UA65636C2 (uk) 1998-10-16 2004-04-15 Ново Нордіск А/С Стабільні концентровані препарати інсуліну для доставки через легені
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
DK1121145T3 (da) 1998-10-16 2002-08-12 Novo Nordisk As Insulinpræparater til indgivelse via lungerne, som indeholder mentol
EP1131089B1 (en) 1998-11-18 2004-02-18 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US6902744B1 (en) 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
DE19908041A1 (de) 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP2007204498A (ja) 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6227819B1 (en) 1999-03-29 2001-05-08 Walbro Corporation Fuel pumping assembly
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
CA2372214A1 (en) 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
BR0010750A (pt) 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
US6978471B1 (en) 1999-05-25 2005-12-20 Thomson Licensing S.A. System for acquiring and processing broadcast programs and program guide data
US6485706B1 (en) 1999-06-04 2002-11-26 Delrx Pharmaceutical Corp. Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
WO2001000223A2 (en) 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
DE19930631A1 (de) 1999-07-02 2001-01-11 Clemens Micheler Spritzvorrichtung zur Injektion mindestens zweier flüssiger Therapeutika, insbesondere Insuline
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
AU7984200A (en) 1999-09-21 2001-04-24 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
DE19947456A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
CZ20021186A3 (cs) 1999-10-04 2002-11-13 Chiron Corporation Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
BR0015294A (pt) 1999-11-03 2003-07-15 Bristol Myers Squibb Co Método para tratamento da diabetes
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
EP1523993A1 (en) 1999-12-16 2005-04-20 Eli Lilly & Company Polypeptide compositions with improved stability
CN1409640A (zh) 1999-12-16 2003-04-09 伊莱利利公司 稳定性改善的多肽组合物
WO2001051071A2 (en) 2000-01-11 2001-07-19 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
US20010012829A1 (en) 2000-01-11 2001-08-09 Keith Anderson Transepithelial delivery GLP-1 derivatives
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001264789A1 (en) 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
US20030212248A1 (en) 2000-07-12 2003-11-13 Furman Thomas Charles Process to increase protein stability
EP1970072A1 (en) 2000-09-18 2008-09-17 Sanos Bioscience A/S Use of GLP-2 peptides for the treatment of hyperparathyroidism
KR100508695B1 (ko) 2001-02-13 2005-08-17 한국과학기술연구원 인슐린의 경구투여용 제형과 그의 제조방법
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
DE10108211A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
DE10108212A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
DE10108100A1 (de) 2001-02-20 2002-08-29 Aventis Pharma Gmbh Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US20020177151A1 (en) 2001-02-26 2002-11-28 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE60233722D1 (de) 2001-04-02 2009-10-29 Novo Nordisk As Insulinvorstufen und verfahren zu deren herstellung
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
US20030026872A1 (en) 2001-05-11 2003-02-06 The Procter & Gamble Co. Compositions having enhanced aqueous solubility and methods of their preparation
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
AU2002318159A1 (en) 2001-06-29 2003-03-03 The Regents Of The University Of California Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
EP1432430A4 (en) 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
US20050013867A1 (en) 2001-10-19 2005-01-20 Lehrman S. Russ Use of proton sequestering agents in drug formulations
WO2003035028A1 (en) 2001-10-19 2003-05-01 Nektar Therapeutics Modulating charge density to produce improvements in the characteristics of spray-dried proteins
DE60236014D1 (de) 2001-11-19 2010-05-27 Novo Nordisk As Verfahren zur herstellung von insulinverbindungen
WO2003053363A2 (en) 2001-12-19 2003-07-03 Millennium Pharmaceuticals, Inc. Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
WO2003066084A1 (en) 2002-02-07 2003-08-14 Novo Nordisk A/S Use of glp-1 compound for treatment of critically ill patients
US20100069293A1 (en) 2002-02-27 2010-03-18 Pharmain Corporation Polymeric carrier compositions for delivery of active agents, methods of making and using the same
TWI351278B (en) 2002-03-01 2011-11-01 Nisshin Pharma Inc Agent for preventing and treating of liver disease
TW200810743A (en) * 2002-03-22 2008-03-01 Novartis Ag Combination of organic compounds
JP5599543B2 (ja) 2002-05-07 2014-10-01 ノヴォ ノルディスク アー／エス 単量体インスリン及びアシル化インスリンを含む可溶性製剤
WO2003094951A1 (en) 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
US7115563B2 (en) 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
WO2004005342A1 (en) 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 and methods for treating diabetes
DE10235168A1 (de) 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
EP2384750A1 (en) 2002-09-27 2011-11-09 Martek Biosciences Corporation Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
BR0314996A (pt) 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
DK1583541T3 (da) 2002-11-20 2011-04-11 Neuronova Ab Forbindelser og fremgangsmåder til at øge neurogenese
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
US20050209142A1 (en) 2002-11-20 2005-09-22 Goran Bertilsson Compounds and methods for increasing neurogenesis
CN1413582A (zh) 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 盐酸二甲双胍肠溶片及其制备方法
WO2004050115A2 (en) 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
GB0309154D0 (en) 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
GB0304822D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
BRPI0408105A (pt) 2003-03-04 2006-03-01 Thetechnology Dev Company Ltd sistema de distribuição para droga e terapia celular
JP2007523842A (ja) 2003-03-11 2007-08-23 ノボ　ノルディスク　アクティーゼルスカブ 酸安定化されたインスリンを含有する薬学的製剤
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
EP1620465A2 (en) 2003-04-29 2006-02-01 Eli Lilly And Company Insulin analogs having protracted time action
EP1633390B1 (en) 2003-06-03 2012-01-18 Novo Nordisk A/S Stabilized pharmaceutical glp-1 peptide compositions
DE10325567B4 (de) 2003-06-05 2008-03-13 Mavig Gmbh Strahlenschutzanordnung mit separierbarer Umhüllung
CA2542372A1 (en) 2003-08-29 2005-03-10 Centocor, Inc. Method of promoting graft survival with anti-tissue factor antibodies
WO2005021022A2 (en) 2003-09-01 2005-03-10 Novo Nordisk A/S Stable formulations of peptides
WO2005023291A2 (en) 2003-09-11 2005-03-17 Novo Nordisk A/S Use of glp1-agonists in the treatment of patients with type i diabetes
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
ES2373660T3 (es) 2003-11-13 2012-02-07 Novo Nordisk A/S Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
WO2005048950A2 (en) 2003-11-17 2005-06-02 Biomune, Inc. Tumor and infectious disease therapeutic compositions
DE602004029496D1 (de) 2003-12-22 2010-11-18 Novo Nordisk As Offbehälter zur lagerung von pharmazeutischen flüssigkeiten
US20060210614A1 (en) 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US7192919B2 (en) 2004-01-07 2007-03-20 Stelios Tzannis Sustained release compositions for delivery of pharmaceutical proteins
US20070027063A1 (en) 2004-01-12 2007-02-01 Mannkind Corporation Method of preserving the function of insulin-producing cells
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20070135338A1 (en) 2004-03-31 2007-06-14 Karyn O'neil Human GLP-1 mimetibodies, compositions, methods and uses
AU2005245240B2 (en) 2004-05-20 2010-04-29 Scimar Ltd. Use of drug combinations for treating insulin resistance
CA2567309A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
WO2006000567A2 (en) 2004-06-28 2006-01-05 Novo Nordisk A/S Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function
WO2006091231A2 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
EP1773376A4 (en) 2004-08-03 2009-07-01 Emisphere Tech Inc ANTIDIBLE ORAL INSULIN BIGUANIDE COMBINATION
ES2309785T3 (es) 2004-08-13 2008-12-16 F. Hoffmann-La Roche Ag Modificacion c-terminal de polipeptidos.
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
US8143391B2 (en) 2004-09-07 2012-03-27 Chugai Seiyaku Kabushiki Kaisha Process for producing water-soluble hyaluronic acid modification
US20060073213A1 (en) 2004-09-15 2006-04-06 Hotamisligil Gokhan S Reducing ER stress in the treatment of obesity and diabetes
JP2008513384A (ja) 2004-09-17 2008-05-01 ノボ ノルディスク アクティーゼルスカブ インスリンおよびインスリン分泌性ペプチドを含有する医薬組成物
JP2006137678A (ja) 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
WO2006051103A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
MX2007005521A (es) 2004-11-12 2007-05-18 Novo Nordisk As Formulaciones estables de peptidos insulinotropicos.
DE102004058306A1 (de) 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
SE0402976L (sv) 2004-12-03 2006-06-04 Mederio Ag Medicinsk produkt
US20070128193A1 (en) 2004-12-22 2007-06-07 O'neil Karyn T GLP-1 agonists, compositions, methods and uses
US7879361B2 (en) 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
US20090142338A1 (en) 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
US20080200383A1 (en) 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
US8097584B2 (en) 2005-05-25 2012-01-17 Novo Nordisk A/S Stabilized formulations of insulin that comprise ethylenediamine
EP1888031B1 (en) 2005-06-06 2013-01-23 Camurus Ab Glp-1 analogue formulations
EP1948161B1 (en) 2005-06-27 2012-01-04 Newtree Co., Ltd. Method for preventing and treating conditions mediated by ppar using macelignan
EP1915334A2 (en) 2005-07-07 2008-04-30 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
PL1971362T3 (pl) 2005-08-19 2015-05-29 Amylin Pharmaceuticals Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
EP1937297A2 (en) 2005-09-08 2008-07-02 Gastrotech Pharma A/S Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
AU2006291780B2 (en) 2005-09-14 2011-12-08 F. Hoffmann-La Roche Ag Cleavage of precursors of insulins by a variant of trypsin
EP1928499B1 (en) 2005-09-20 2011-06-29 Novartis AG Use of a dpp-iv inhibitor to reduce hypoglycemic events
CN101267838B (zh) * 2005-09-20 2012-09-05 诺瓦提斯公司 Dpp-iv抑制剂降低低血糖事件的用途
WO2007038540A1 (en) 2005-09-26 2007-04-05 Medtronic, Inc. Prosthetic cardiac and venous valves
DE102005046113A1 (de) 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
KR101105871B1 (ko) 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007044867A2 (en) 2005-10-11 2007-04-19 Huntington Medical Research Institutes Imaging agents and methods of use thereof
RU2395218C2 (ru) 2005-10-24 2010-07-27 Нестек С.А. Композиция пищевых волокон для профилактики или лечения заболеваний пищеварительной системы и композиция пищевых волокон, эффективная при лечении холеры
CN101309668A (zh) 2005-11-30 2008-11-19 健乐克斯医药公司 经口吸收的药物制剂和用药方法
US20100029558A1 (en) 2005-12-06 2010-02-04 Bristow Cynthia L Alpha1 proteinase inhibitor peptides methods and use
EP2364735A3 (en) 2005-12-16 2012-04-11 Nektar Therapeutics Branched PEG conjugates of GLP-1
EP2913056A1 (en) 2006-01-05 2015-09-02 The University of Utah Research Foundation Methods and compositions related to improving properties of pharmacological agents targeting nervous system
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
US20090324701A1 (en) 2006-01-20 2009-12-31 Diamedica, Inc. Compositions containing (s)-bethanechol and their use in the treatment of insulin resistance, type 2 diabetes, glucose intolerance and related disorders
US20070191271A1 (en) 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
WO2007095288A2 (en) 2006-02-13 2007-08-23 Nektar Therapeutics Methionine-containing protein or peptide compositions and methods of making and using
WO2007098479A2 (en) 2006-02-21 2007-08-30 University Of Medicine And Dentistry Of New Jersey Localized insulin delivery for bone healing
EP1996224B1 (en) 2006-03-15 2012-11-07 Novo Nordisk A/S Mixtures of amylin and insulin
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
JP2009532422A (ja) 2006-04-03 2009-09-10 ノボ・ノルデイスク・エー／エス Ｇｌｐ−１ペプチドアゴニスト
CN101454019A (zh) 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
MX2008013168A (es) 2006-04-13 2008-10-27 Sod Conseils Rech Applic Composiciones faramaceuticas del peptido 1 similar al glucagon humano, exendina-4 y análogos de los mismos.
US20090099064A1 (en) 2006-06-08 2009-04-16 Diabecore Medical Inc., Derivatized insulin oligomers
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
JP2009544716A (ja) 2006-07-27 2009-12-17 ノバルティス アクチエンゲゼルシャフト 肺送達のためのインスリン含有エアロゾル化可能製剤
WO2008021560A2 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
WO2008023050A1 (en) 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
WO2008028914A1 (en) 2006-09-07 2008-03-13 Nycomed Gmbh Combination treatment for diabetes mellitus
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
WO2008124522A2 (en) 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2008145323A1 (en) 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
WO2008151737A1 (de) 2007-06-14 2008-12-18 Sanofi-Aventis Deutschland Gmbh Zweikammerkarpule
DK2167169T4 (en) 2007-06-14 2016-05-30 Sanofi Aventis Deutschland Tokammerkarpule with accessories
EP2173407B1 (en) 2007-07-02 2020-02-19 Roche Diabetes Care GmbH A device for drug delivery
US20090324609A1 (en) 2007-08-09 2009-12-31 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
JP5710253B2 (ja) 2007-08-13 2015-04-30 ノボ・ノルデイスク・エー／エス 速効型インスリンアナログ
CN101366692A (zh) 2007-08-15 2009-02-18 江苏豪森药业股份有限公司 一种稳定的艾塞那肽制剂
GB0717399D0 (en) 2007-09-07 2007-10-17 Uutech Ltd Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
GB0717388D0 (en) 2007-09-07 2007-10-17 Uutech Ltd Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
AU2008310076A1 (en) 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag CGRP as a therapeutic agent
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
BRPI0818324B8 (pt) 2007-11-01 2021-05-25 Merck Serono Sa formulação líquida contendo hormônio luteinizante (lh) ou uma variante do mesmo, seu uso, sua forma de apresentação, processo para a sua preparação e composição farmacêutica
EP2217621B1 (en) 2007-11-08 2015-04-22 Novo Nordisk A/S Insulin derivative
BRPI0820535B8 (pt) 2007-11-16 2021-05-25 Novo Nordisk As composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
CN101444618B (zh) 2007-11-26 2012-06-13 杭州九源基因工程有限公司 含有艾塞那肽的药物制剂
JP2011506442A (ja) 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
EP2234644B1 (en) 2008-01-04 2013-07-31 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
MY152979A (en) 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
JP5695909B2 (ja) 2008-01-09 2015-04-08 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
NZ586588A (en) 2008-02-08 2012-10-26 Biogenerix Ag Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
RU2495131C2 (ru) 2008-02-19 2013-10-10 Байокон Лимитид Способ получения рекомбинантного инсулина гларгина
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
JP2011523052A (ja) 2008-05-23 2011-08-04 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｌｐ−１受容体アゴニスト・バイオアッセイ
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
CN102131516B (zh) 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
CA2735289A1 (en) 2008-08-30 2010-03-04 Sanofi-Aventis Deutschland Gmbh Cartridge and needle system therefor
WO2010028055A1 (en) 2008-09-02 2010-03-11 Biodel, Inc. Insulin with a basal release profile
CN103599541A (zh) 2008-09-10 2014-02-26 弗·哈夫曼-拉罗切有限公司 用于防止蛋白质氧化降解的组合物和方法
CN101670096B (zh) 2008-09-11 2013-01-16 杭州九源基因工程有限公司 含有艾塞那肽的药物制剂
CN102281865B (zh) 2008-10-15 2017-04-05 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
JP4959005B2 (ja) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
JP2009091363A (ja) 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Ｐｔｈの安定化水溶液注射剤
CN102282167B (zh) * 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
JP5677321B2 (ja) 2009-02-04 2015-02-25 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 血糖コントロール用の情報を提供するための医療デバイス及び方法
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
EP2435061A4 (en) 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
US20120241356A1 (en) 2009-07-06 2012-09-27 Sanofi-Aventis Deutschland Gmbh Heat- and vibration-stable insulin preparations
JP5675799B2 (ja) 2009-07-06 2015-02-25 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 遅効性インスリン製剤
US8709400B2 (en) 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
NZ597964A (en) 2009-07-31 2014-04-30 Sanofi Aventis Deutschland Long acting insulin composition
US8642548B2 (en) 2009-08-07 2014-02-04 Mannkind Corporation Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
PL2329848T5 (pl) 2009-11-13 2019-12-31 Sanofi-Aventis Deutschland Gmbh Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
CA2685638C (en) 2009-11-13 2017-02-28 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
PL2324853T3 (pl) 2009-11-13 2016-01-29 Sanofi Aventis Deutschland Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2
US20110118180A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
WO2011075623A1 (en) 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
PH12012501557A1 (en) 2010-02-22 2012-10-22 Univ Case Western Reserve Long-acting insulin analogue preparations in soluble and crystalline form
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
AR080884A1 (es) 2010-04-14 2012-05-16 Sanofi Aventis Conjugados de insulina-sirna
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2011144674A2 (en) 2010-05-20 2011-11-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
WO2011160066A1 (en) 2010-06-17 2011-12-22 Regents Of The University Of Minnesota Production of insulin producing cells
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
WO2012012352A2 (en) 2010-07-19 2012-01-26 Amidebio, Llc Modified peptides and proteins
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
PL2632478T3 (pl) 2010-10-27 2020-03-31 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
WO2012065996A1 (en) 2010-11-15 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN
WO2012066086A1 (en) 2010-11-17 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN
WO2012080320A1 (en) 2010-12-14 2012-06-21 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
AU2012213435B2 (en) 2011-02-02 2017-03-30 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
US20120277147A1 (en) 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US8735349B2 (en) 2011-05-13 2014-05-27 Sanofi-Aventis Deutschland Gmbh Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20130040878A1 (en) 2011-05-13 2013-02-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in the treatment of diabetes type 2 patients
PT2707017E (pt) 2011-05-13 2016-01-12 Sanofi Aventis Deutschland Lixisenatida e metformina para tratamento da diabetes tipo 2
WO2012177929A2 (en) 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013050378A1 (en) 2011-10-04 2013-04-11 Sanofi-Aventis Deutschland Gmbh Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
PL2763690T3 (pl) 2011-10-04 2016-04-29 Sanofi Aventis Deutschland Liksysenatyd do stosowania w leczeniu stenozy i/lub niedrożności w układzie przewodów trzustkowych
MX359329B (es) 2011-10-28 2018-09-25 Sanofi Aventis Deutschland Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2.
US20130172244A1 (en) * 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US8901484B2 (en) 2012-04-27 2014-12-02 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
US9522235B2 (en) 2012-05-22 2016-12-20 Kaleo, Inc. Devices and methods for delivering medicaments from a multi-chamber container
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
DK2968471T3 (en) 2013-03-01 2017-10-23 Fundació Hospital Univ Vall D' Hebron - Inst De Recerca Peptides for use in the topical treatment of retinal neurodegenerative diseases, especially in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
GB201303771D0 (en) 2013-03-04 2013-04-17 Midatech Ltd Nanoparticles peptide compositions
UA117480C2 (uk) 2013-04-03 2018-08-10 Санофі Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
JP6438944B2 (ja) * 2013-06-17 2018-12-19 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比率製剤
TW201605489A (zh) 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI706779B (zh) 2015-01-16 2020-10-11 德商賽諾菲阿凡提斯德意志有限公司 小兒第２型糖尿病病患之治療
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117909B2 (en) 2008-10-17 2018-11-06 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
US12303598B2 (en) 2009-11-13 2025-05-20 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1-agonist and methionine
US12186374B2 (en) 2014-12-12 2025-01-07 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients

Also Published As

Publication number Publication date
KR102694473B1 (ko) 2024-08-13
JP6857129B2 (ja) 2021-04-14
EP3268029B1 (en) 2022-04-27
PH12017501662A1 (en) 2018-03-19
KR20170123699A (ko) 2017-11-08
JP2018509419A (ja) 2018-04-05
TN2017000373A1 (en) 2019-01-16
ES2922551T3 (es) 2022-09-16
TW201705974A (zh) 2017-02-16
CL2017002293A1 (es) 2018-05-04
IL254496A0 (en) 2017-11-30
CA2979448A1 (en) 2016-09-22
TWI748945B (zh) 2021-12-11
MA42287A (fr) 2021-06-02
US20180092965A1 (en) 2018-04-05
AU2016232448A1 (en) 2017-11-02
AU2016232448C1 (en) 2021-09-16
MX389091B (es) 2025-03-20
SG11201707372YA (en) 2017-10-30
EP3268029A1 (en) 2018-01-17
BR112017018388A2 (pt) 2018-04-17
AR103914A1 (es) 2017-06-14
MA42287B1 (fr) 2022-08-31
US10434147B2 (en) 2019-10-08
EA201792030A1 (ru) 2018-01-31
EA034940B1 (ru) 2020-04-09
PL3268029T3 (pl) 2022-08-16
PT3268029T (pt) 2022-07-18
NZ736299A (en) 2023-02-24
IL254496B (en) 2022-02-01
MX2017011723A (es) 2017-11-13
HK1244216A1 (zh) 2018-08-03
WO2016146514A1 (en) 2016-09-22
CN107921099A (zh) 2018-04-17
AU2016232448B2 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
US10434147B2 (en) Treatment type 2 diabetes mellitus patients
US20220054594A1 (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
JP6329487B2 (ja) ２型糖尿病の治療プロトコル
JP6676108B2 (ja) ２型糖尿病の処置のためのリキシセナチド及びメトホルミン
US20240173384A1 (en) Treatment of pediatric type 2 diabetes mellitus patients
JP6410600B2 (ja) ２型糖尿病患者における低血糖症の予防
US20110118180A1 (en) Method of treatment of diabetes type 2 comprising add-on therapy to metformin
DK3010530T3 (en) FIXED-FORMULATED FORMULATION BETWEEN INSULIN GLARGIN AND LIXISENATIDE
CN107375909A (zh) 在2型糖尿病患者中预防低血糖症
KR20140038410A (ko) 2형 당뇨병에서 기저 인슐린에 대한 부가 치료요법으로서의 릭시세나티드
HUE027989T2 (en) A pharmaceutical composition for use in glycemic control in patients with type 2 diabetes
US20250319163A1 (en) Treatment of type 2 diabetes mellitus
KR20110052990A (ko) 인슐린 글라르긴 및 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법
HK1244216B (en) Treatment of type 2 diabetes mellitus patients
BR112017018388B1 (pt) Uso de combinação farmacêutica para o controle da glicemia em indivíduo com diabetes mellitus tipo 2
KR20110052987A (ko) 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법
HK1198577B (en) Treatment protocol of diabetes type 2

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROY, CHRISTINE;SOUHAMI, ELISABETH;DEMIL, NACIMA;AND OTHERS;SIGNING DATES FROM 20160415 TO 20160608;REEL/FRAME:039120/0893

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION